Ishita Drugs & Inds.
Ticker > Company >

Ishita Drugs & Inds. share price

Ishita Drugs & Industries Ltd.

BSE: 524400 SECTOR: Pharmaceuticals & Drugs  12.29 K   44   3

75.10
0 0
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 77.98

Today's Low

₹ 75.1

52 Week High

₹ 99.64

52 Week Low

₹ 62.35

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 22.46 Cr.

Enterprise Value

₹ 17.65 Cr.

No. of Shares

0.3 Cr.

P/E

21.95

P/B

2.02

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  37.09

CASH

₹ 4.81 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

49.92 %

EPS (TTM)

₹  3.42

Sales Growth

25.81%

ROE

7.84 %

ROCE

10.74%

Profit Growth

29.63 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.81%
3 Year2.88%
5 Year10.82%

Profit Growth

1 Year29.63%
3 Year-3.37%
5 Year16.32%

ROE%

1 Year7.84%
3 Year8.05%
5 Year8.72%

ROCE %

1 Year10.74%
3 Year10.88%
5 Year11.56%

Debt/Equity

0

Price to Cash Flow

10.59

Interest Cover Ratio

11.9989

CFO/PAT (5 Yr. Avg.)

0.761871223801924

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 49.92 0.00
Mar 2025 49.91 0.00
Dec 2024 49.85 0.00
Sep 2024 49.80 0.00
Jun 2024 49.80 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 0.9604251 Cr.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.740775862072588.
  • The company has an efficient Cash Conversion Cycle of 40.6543 days.
  • Company has a healthy liquidity position with current ratio of 11.1352.

 Limitations

  • The company has shown a poor profit growth of -3.37178904698935% for the Past 3 years.
  • The company has shown a poor revenue growth of 2.87624920066223% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 3.03 3.27 4.13 4.56 5.4
Total Expenditure 2.85 3.04 3.84 4.27 5.05
Operating Profit 0.17 0.24 0.3 0.29 0.35
Other Income 0.06 0.05 0.07 0.16 0.09
Interest 0.01 0 0.02 0.04 0.02
Depreciation 0.03 0.03 0.03 0.03 0.03
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.2 0.26 0.32 0.38 0.39
Tax 0.05 0.06 0.08 0.1 0.09
Profit After Tax 0.15 0.2 0.24 0.29 0.3
Adjusted EPS (Rs) 0.49 0.65 0.8 0.96 1.01

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 14.83 13.95 14.09 12.07 15.19
Total Expenditure 14.07 13.03 13 11.31 14.28
Operating Profit 0.76 0.92 1.09 0.76 0.91
Other Income 0.16 0.31 0.11 0.2 0.28
Interest 0.03 0.03 0.02 0.05 0.09
Depreciation 0.18 0.15 0.13 0.13 0.11
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.71 1.05 1.04 0.78 0.99
Tax 0.17 0.22 0.24 0.2 0.24
Net Profit 0.55 0.83 0.8 0.58 0.75
Adjusted EPS (Rs.) 1.83 2.77 2.69 1.93 2.5

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 2.99 2.99 2.99 2.99 2.99
Total Reserves 3.97 4.8 5.61 6.18 6.93
Borrowings 0.04 0 0 0 0
Other N/C liabilities 0.05 0.04 0.03 0.02 0.02
Current liabilities 2.5 1.43 2.63 2.21 0.87
Total Liabilities 9.55 9.26 11.25 11.41 10.81
Assets
Net Block 1.14 1 0.88 0.89 0.8
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.21 0.23 0.27 0.27 0.27
Loans & Advances 0.05 0.05 0.05 0.07 0.08
Other N/C Assets 0 0 0 0 0
Current Assets 8.15 7.99 10.05 10.18 9.66
Total Assets 9.55 9.26 11.25 11.41 10.81
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 0.71 1.05 1.04 0.78 0.99
Adjustment 0.05 -0.14 0.05 -0.02 -0.08
Changes in Assets & Liabilities 0.46 -1.36 2.24 -3.45 1.45
Tax Paid -0.18 -0.23 -0.25 -0.21 -0.24
Operating Cash Flow 1.05 -0.67 3.08 -2.9 2.12
Investing Cash Flow -1.15 2.45 -0.93 0.59 0.13
Financing Cash Flow 0.09 -0.24 0 1.05 -0.87
Net Cash Flow -0.01 1.54 2.14 -1.25 1.38

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 49.80 49.80 49.85 49.91 49.92
abha agrawal 8.37 8.37 8.39 8.39 8.39
agrawal jagdishprasad g 2.84 2.84 2.84 2.84 2.84
divya sumit agrawal 3.48 3.48 3.48 3.48 3.48
ishita agrawal 0.84 0.84 0.84 0.84 0.84
ishita overseas private l... 4.35 4.35 4.35 4.35 4.35
krishn sumit agrawal 3.01 3.01 4.68 4.68 4.68
shri jagdish agrawal 5.86 5.86 4.22 4.28 4.29
sumit agrawal 9.77 9.77 9.77 9.77 9.77
umang financial services ... 9.94 9.94 9.94 9.94 9.94
varlika sumit agrawal 1.34 1.34 1.34 1.34 1.34
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 50.20 50.20 50.15 50.09 50.08
mahendra girdharilal wadh... 1.00 1.37 1.98 2.15 2.15
mohan deep chandiramani h... - - 1.18 1.18 1.22
patel bhupesh vahalabhai 3.43 1.84 1.84 1.84 1.84
rajan malhotra - - 1.28 1.28 1.28
sangeetha s 1.27 1.27 1.27 1.27 1.00
vikkramm chandirramani - 1.35 1.35 1.35 1.35

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Ishita Drugs & Inds. - Quaterly Results 12 Aug, 5:28 PM Ishita Drugs & Inds. - Quaterly Results 12 Aug, 5:28 PM Ishita Drugs & Inds. - Quaterly Results 12 Aug, 5:28 PM Ishita Drugs & Industries submits board meeting intimation 23 May, 5:12 PM Ishita Drugs & Industries informs about disclosure 1 Mar, 4:01 PM Ishita Drugs & Inds. - Quaterly Results 13 Feb, 5:57 PM Ishita Drugs & Industries informs about closure of trading window 27 Dec, 5:04 PM Ishita Drugs & Inds. - Quaterly Results 13 Aug, 7:18 PM Ishita Drugs & Industries informs about compliances-certificate 9 Apr, 4:55 PM Ishita Drugs & Inds. - Quaterly Results 13 Feb, 7:37 PM Ishita Drugs & Inds. - Quaterly Results 13 Feb, 7:37 PM Ishita Drugs and Industries informs about certificate 14 Apr, 4:27 PM Ishita Drugs and Industries informs about outcome of board meeting 14 Nov, 5:05 PM Ishita Drugs & Industries receives Environmental Clearance from SEIAA 13 Sep, 9:45 AM Ishita Drugs and Company Secretary Industries informs about confirmation certificate 13 Jul, 4:51 PM Ishita Drugs & Industries informs about closure of trading window 1 Jul, 2:58 PM Ishita Drugs & Industries informs about annual secretarial compliance report 11 May, 4:34 PM Ishita Drugs & Industries informs about confirmation certificate 13 Jan, 4:28 PM Ishita Drugs & Industries informs about confirmation certificate 13 Jul, 2:19 PM Ishita Drugs & Industries informs about closure of trading window 1 Jul, 5:02 PM Ishita Drugs & Industries submits compliance certificate 15 Apr, 4:23 PM

Ishita Drugs & Inds. Stock Price Analysis and Quick Research Report. Is Ishita Drugs & Inds. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Ishita Drugs & Inds.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Ishita Drugs & Inds. has a PE ratio of 21.9520037414867 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Ishita Drugs & Inds. has ROA of 6.7384% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Ishita Drugs & Inds. has a Current ratio of 11.1352.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Ishita Drugs & Inds. has a ROE of 7.8399%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Ishita Drugs & Inds. has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Ishita Drugs & Inds. has reported revenue growth of 25.805% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Ishita Drugs & Inds. for the current financial year is 5.98159976063097%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Ishita Drugs & Inds. is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Ishita Drugs & Inds. is Rs 3.4211. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Ishita Drugs & Inds. in Ticker for free. Also, one can get the intrinsic value of Ishita Drugs & Inds. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Ishita Drugs & Inds. FAQs

Q1. What is Ishita Drugs & Inds. share price today?
Ans: The current share price of Ishita Drugs & Inds. is Rs 75.1.

Q2. What is the market capitalisation of Ishita Drugs & Inds.?
Ans: Ishita Drugs & Inds. has a market capitalisation of Rs 22.457153 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Ishita Drugs & Inds.?
Ans: The PE ratio of Ishita Drugs & Inds. is 21.9520037414867 and the P/B ratio of Ishita Drugs & Inds. is 2.02456981261272, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Ishita Drugs & Inds. share?
Ans: The 52-week high share price of Ishita Drugs & Inds. is Rs 99.64, and the 52-week low share price of Ishita Drugs & Inds. is Rs 62.35.

Q5. Does Ishita Drugs & Inds. pay dividends?
Ans: Currently, Ishita Drugs & Inds. does not pay dividends. Dividend yield of Ishita Drugs & Inds. is around 0%.

Q6. What are the face value and book value of Ishita Drugs & Inds. shares?
Ans: The face value of Ishita Drugs & Inds. shares is Rs 10, while the book value per share of Ishita Drugs & Inds. is around Rs 37.0943. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Ishita Drugs & Inds.?
Ans: Ishita Drugs & Inds. has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Ishita Drugs & Inds.?
Ans: The ROE of Ishita Drugs & Inds. is 7.8399% and ROCE of Ishita Drugs & Inds. is 10.7406%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Ishita Drugs & Inds. a good buy for the long term?
Ans: The Ishita Drugs & Inds. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Ishita Drugs & Inds. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Ishita Drugs & Inds. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Ishita Drugs & Inds.’s financials?
Ans: You can review Ishita Drugs & Inds.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Ishita Drugs & Inds.
X